LeonaBio GAAP EPS of -$24.70

What: LeonaBio reported a GAAP EPS of -$24.70, indicating significant net losses.
Why: The company's financial performance was likely impacted by high research and development expenses, as well as potential delays in product commercialization.
Signal: This EPS result may signal a challenging road ahead for LeonaBio, potentially affecting investor confidence and stock performance.
Target: The company may need to re-evaluate its business strategy and cost structure to achieve profitability targets.
Risk: The high risk of net losses and potential cash burn may pose a significant risk to LeonaBio's long-term viability and ability to attract future funding.